Advancing Representative Enrollment in Clinical Trials
Virtual Public Webinar
July 18, 2023
12:00-4:00 Eastern

Agenda

Meeting Objective:
This public meeting will explore challenges to achieving representative enrollment in clinical trials. Topics discussed will include opportunities to synthesize best practices where possible and identify policy levers for achieving measurable change. We will also explore learnings and examples from the current clinical trial landscape with an eye towards improving clinical trial conduct across a broad range of clinical sites and locations by advancing pragmatic trial principles. Panel discussions will focus on critically examining actionable steps various stakeholders can take to advance the mission of representative trial enrollment.

12:00 p.m.  Welcome and Opening Remarks
Trevan Locke, Duke-Robert J. Margolis, MD, Center for Health Policy

12:10 p.m.  Introduction: Key Terminology, Meeting Goals, Level Setting
Trevan Locke, Duke-Robert J. Margolis, MD, Center for Health Policy

12:25 p.m.  Session 1: Defining the Current Clinical Trial Landscape
Objective: This session will describe current challenges to achieving representative trial enrollment from the perspective of various stakeholders. Panelists will discuss the best ways to measure success in achieving representation goals, the impact of the current policy and regulatory landscape, and progress made in recent years to advance representative trial enrollment.

Moderator: Trevan Locke, Duke-Robert J. Margolis, MD, Center for Health Policy

Presentation: Measuring Clinical Trial Representativeness
Jen Miller, Yale School of Medicine

Panel Discussion
• Jen Miller, Yale School of Medicine
• Lola Fashoyin-Aje, Oncology Center of Excellence, FDA
• Sneha Dave, Generation Patient

1:25 p.m.  Break

1:35 p.m.  Session 2: Building Capacity for Representative Trials in Community Settings
Objective: This session will discuss broad strategies and areas of opportunity for improving representative trial enrollment through community engagement and capacity building. Panelists will discuss alternative approaches to conducting clinical trials, explore the role of education and community partnerships in promoting representative enrollment, and consider current financial, technological, and cultural barriers to trial implementation in community settings.
Moderator: Andrea Thoumi, Duke-Robert J. Margolis, MD, Center for Health Policy
Opening Remarks: Sandra Yankah, Duke-Robert J. Margolis, MD, Center for Health Policy

Panel Discussion
- Nadine Barrett, Duke CTSI Center for Equity in Research
- Perla Nunes, Julius L. Chambers Biomedical Biotechnology Research Institute
- Yasmeen Long, FasterCures
- Jennifer Byrne, Javara

2:35 p.m.  Fireside Chat
Mark McClellan, Duke-Robert J. Margolis, MD, Center for Health Policy
Kirsten Bibbins-Domingo, JAMA; University of California, San Francisco

2:55 p.m.  Session 3: Defining the Role of Various Stakeholders in Improving Trial Representation
Objective: This session will discuss actionable next steps for various stakeholders and relevant accountability measures for ensuring progress on trial representation efforts. Discussion will include strategies for fostering a culture of representative and trustworthy research, the potential role of point-of-care trial and other innovative trial approaches, avenues for introducing or refining policies to encourage representative enrollment, and strategies for addressing remaining gaps to operationalizing representative enrollment.

Moderator: Mark McClellan, Duke-Robert J. Margolis, MD, Center for Health Policy

Presentation: Overview of Duke-Margolis preliminary recommendations
Trevan Locke, Duke-Robert J. Margolis, MD, Center for Health Policy

Panel Remarks:
- Sara Calvert, Clinical Trials Transformation Initiative
- Carla Rodriguez-Watson, Reagan Udall Foundation for the FDA
- Salina Waddy, National Center for Advancing Translational Sciences
- Megan McKenzie, Genentech
- Silas Buchanan, Institute for eHealth Equity

3:55 p.m.  Closing Remarks
4:00 p.m.  Adjournment

Support for this event was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.